The basal-plus strategy is potentially suitable for a large number of individuals with Type 2 diabetes, and may delay their progression to a full insulin replacement regimen, especially when the initiation of insulin therapy is not delayed. The gene discussed is INS; the disease is type 2 diabetes mellitus.